“We engineer the delivery so gene therapies can deliver the cure.”
Klara Grantz Saskova
Chief Executive Officer
At Adalid, we advance gene therapies with next-generation lipid nanoparticles (LNPs) engineered to improve nucleic-acid efficacy, biodistribution, stability, and cell-type targeting, raising the therapeutic index while reducing off-target effects.
Based in the heart of Europe, in Prague, Czech Republic, Adalid was established in June 2024 as a spin-off from the Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences. Our foundation is built on a legacy of scientific excellence and innovation.
With the financial backing of a robust and committed partner, we are well-equipped to pursue long-term cooperation and bring our groundbreaking technology to partners and clients worldwide. This strategic support enables us to accelerate our research and development efforts, fostering collaborations that push the boundaries of genomic medicine and beyond. With our strong background in synthetic chemistry, nanoparticle formulation and biology, we can provide added value and seamlessly integrate into our clients' workflows.
Strong scientific background
Multidisciplinary, international team
Fully equipped labs for all R&D stages
Strong IP and continuous R&D
Instrument development pipeline
Our team has accumulated decades of expertise in using lipid nanoparticles as a delivery system for nucleic acids and related fields.
We are proud to have built an expert team of scientists ready to advance our clients' projects and continue developing our technology. With 5 nationalities and over 70 % share of Ph.D. holders, our diversified staff brings top class expertise in the areas related to LNPs, including synthetic chemistry, nanochemistry, analytical chemistry, biochemistry and biology. Working in newly equipped laboratories, we are looking forward to tackling all challenges brought to us by our partners.
Klara Grantz Saskova
Co-Founder and Chief Executive Officer
Klara has successfully led the LNP project at IOCB Prague for three years, guiding it from academia to a standalone spin-off company. In addition to her work on LNPs, she is an expert in biochemistry and leads a research group at Charles University focusing on medicinal chemistry and virology. Her distinguished career is connected to both the IOCB and her alma mater, the Faculty of Science at Charles University.
Read more
Petr Cigler
Co-Founder and Chief Scientific Officer
Petr is a distinguished Czech scientist who turned his innate childhood curiosity into a successful career, culminating in a PhD in chemistry. After two years at the Scripps Research Institute (CA), he returned to Prague where he leads a research group at IOCB. In his spare time, Petr pursues his passion for music by playing the French horn and has received critical acclaim as a composer of modern instrumental music and operas.
Read more
Frantisek Sedlak
Co-Founder and Chief Medical Officer
František As a trained physician, Frantisek continues to see his patients at a leading medical institution. In Adalid he will focus on the regulatory approval of our products and oversees the medical implications of the application of our technology. As an active scientistific researcher, Frantise also supervises the operations revolving around the formulation of our LNPs.
Read more
David Schreib
Co-Founder and Chief Commercial Officer
David has broad experience in both legal and business affairs in private as well as public sector. David manages the commercial, legal and operational aspects of Adalid Sciences, ensuring that our scientific teams have the best possible conditions to excel in their work and that our clients feel confident in their partnership with Adalid Sciences.
Read more
Andrea Brazdova
Head of Biology
Andrea is a senior immunologist bridging mechanistic biology with therapeutic development. She earned her PhD from UPMC Paris and UCT Prague and completed postdoctoral training in immunoregulation and cellular therapy for graft-versus-host disease. Her scientific record also spans mitochondrial biology and STING-mediated immunomodulation across antiviral/oncology indications. At Adalid Sciences, she leads biological validation of next-generation lipid nanoparticles, linking formulation design with in vitro functionality and in vivo validation to accelerate nucleic acid medicines toward clinical impact.
Read more
Alessandro Jäger
Head of Nanochemistry
With over two decades of expertise in macromolecular physical chemistry at the IMC in Prague, he has devoted his career to translating fundamental principles of physical chemistry into impactful biomedical applications. A recognized specialist in the microfluidic self-assembly of biomaterials, he coordinates the team at Adalid that develops advanced drug delivery systems, enhancing the precision, targeting, and efficacy of next-generation therapeutics.
Read more
Eliezer Jäger
Head of Chemistry
Eliezer has led innovative research at the intersection of stimuli-responsive polymers, advanced polymerization techniques, and targeted drug delivery systems at IMC-CAS for over 16 years. With expertise in polymer chemistry, nanomedicine, and drug delivery, his work drives development of advanced, stimuli-responsive polymer materials for biomedical innovation.
Read more
Ondrej Navratil
Head of Instrument Development
Ondrej combines chemical engineering knowledge with rapid prototyping proficiency. His experience in nanotechnology research at UCT Prague and Adalid Sciences entails advanced pharmaceutical product development and characterization now allowing him to create specialized instruments tailored for complex scientific needs.
Read more
Filip Hladek
Head of ML Engineering & Data Science
Filip drives technical innovation in R&D through advanced Machine Learning engineering and custom neural networks. Leveraging research from UCT Prague and Universität Wien, he builds scientifically accurate AI tools to interpret complex experimental data. His expertise transforms raw data into predictive models that optimize formulation.
Read more
Andrea Brazdova
Head of Biology
Andrea is a senior immunologist bridging mechanistic biology with therapeutic development. She earned her PhD from UPMC Paris and UCT Prague and completed postdoctoral training in immunoregulation and cellular therapy for graft-versus-host disease. Her scientific record also spans mitochondrial biology and STING-mediated immunomodulation across antiviral/oncology indications. At Adalid Sciences, she leads biological validation of next-generation lipid nanoparticles, linking formulation design with in vitro functionality and in vivo validation to accelerate nucleic acid medicines toward clinical impact.
Alessandro Jäger
Head of Nanochemistry
With over two decades of expertise in macromolecular physical chemistry at the IMC in Prague, he has devoted his career to translating fundamental principles of physical chemistry into impactful biomedical applications. A recognized specialist in the microfluidic self-assembly of biomaterials, he coordinates the team at Adalid that develops advanced drug delivery systems, enhancing the precision, targeting, and efficacy of next-generation therapeutics.
Eliezer Jäger
Head of Chemistry
Eliezer has led innovative research at the intersection of stimuli-responsive polymers, advanced polymerization techniques, and targeted drug delivery systems at IMC-CAS for over 16 years. With expertise in polymer chemistry, nanomedicine, and drug delivery, his work drives development of advanced, stimuli-responsive polymer materials for biomedical innovation.
Ondrej Navratil
Head of Instrument Development
Ondrej combines chemical engineering knowledge with rapid prototyping proficiency. His experience in nanotechnology research at UCT Prague and Adalid Sciences entails advanced pharmaceutical product development and characterization now allowing him to create specialized instruments tailored for complex scientific needs.
Filip Hladek
Head of ML Engineering & Data Science
Filip drives technical innovation in R&D through advanced Machine Learning engineering and custom neural networks. Leveraging research from UCT Prague and Universität Wien, he builds scientifically accurate AI tools to interpret complex experimental data. His expertise transforms raw data into predictive models that optimize formulation.
Next-generation lipid nanoparticles for gene delivery.
Billing information
Adalid Sciences, s.r.o.
Podbabska 2582/30
160 00, Praha 6
Czech Republic
Reg. No 21691053
VAT No CZ21691053
